Health Care · Biological Products, (No Diagnostic Substances)

TNYA Tenaya Therapeutics Inc SEC Filings & Insider Trading Activity 2026

company
CIK 185884860 filings

TNYA at a glance

Tenaya Therapeutics Inc (TNYA, SEC CIK 1858848) filed its latest 10-K annual report on March 11, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of September 30, 2026, 18 institutional investment managers tracked by SignalX reported holding Tenaya Therapeutics Inc (TNYA) shares worth $20.1 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Ali Faraz on November 17, 2026 of 3,499 shares at $0.32 per share.
  • In the last 90 days, TNYA insiders reported 0 open-market purchases ($0) and 2 open-market sales ($2K) on Form 4, a net sale of $2K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
0 buys · 2 sells
Net −$2K
13F holders
18 funds
$20.1M · −3 vs prior quarter
Latest 8-K
Nov 4, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Quarterly revenue $1.7M, versus none YoY, entirely collaboration revenue
  • Net loss $18.9M vs $20.3M YoY, operating loss $19.6M vs $20.9M
  • Clinical R&D highest-performing category, $6.2M, up 52% YoY; manufacturing lowest, $1.5M, down 64%
  • Cash and equivalents $66.8M at September 30, 2026; operating cash use $40.5M year-to-date
  • Outlook: cash sufficient through at least next twelve months; pivotal-trial regulatory updates planned by year end

Risk Factors

  • Newly added tax risk: California’s temporary state NOL suspension applies to taxable years 2024, 2025 and 2026
  • Manufacturing risk: Closure of the GMMC may require comparability studies, regulatory filings and facility approvals for TN-201 and TN-401
  • Regulatory risk: February 2026 legislation permits FDA approval of multiple versions of orphan drugs across subindications and subpopulations
  • Operational risk: FDA placed MyPEAK-1 on clinical hold in November 2025, later lifted after protocol amendments
  • Financial risk: Cash and cash equivalents totaled $66.8 million at September 30, 2026, against an accumulated deficit of $686.6 million

AI summary of the TNYA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Tenaya’s earnings release covers the quarter ended September 30, 2026
  • Exhibit 99.1 contains the financial results and management disclosures relevant to investors

Item EX-99.1: Item EX-99.1

  • Q3 2026 net loss $18.9M, or $0.08 per share, improved from $20.3M, or $0.12, year over year
  • Cash $66.8M supports planned operations into Q4 2027, reducing near-term financing pressure but not eliminating funding risk
Filed Aug 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Tenaya’s earnings release covers the quarter ended June 30, 2026
  • Exhibit 99.1 contains the company’s financial results and management commentary

Item EX-99.1: Item EX-99.1

  • Q2 2026 net loss $43.4M, or $0.20 per share, including a $21.8M non-cash GMMC lease impairment
  • Cash $78.1M, funding planned operations through Q3 2027 and reducing near-term financing pressure
Filed Jul 2, 2026Full analysis →

Item 1.02: Termination of a Material Definitive Agreement

  • Union City GMMC lease ends August 31, 2026, versus original July 2031 expiration
  • Cost reduction from decommissioned 94,046-square-foot manufacturing facility

AI summaries of TNYA 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for TNYA

Don't miss the next TNYA filing

  • Alerts as it files. A push when TNYA files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut TNYA, by share count.
  • Ask anything. An AI agent that reads every TNYA filing and answers with sources.

TNYA alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Ali FarazSellNov 17, 2026$0.32
Tingley WhittemoreSellNov 17, 2026$0.32
Ali FarazASep 10, 2026-
Tingley WhittemoreASep 10, 2026-
Ali FarazASep 10, 2026-
Tingley WhittemoreASep 10, 2026-
Tingley WhittemoreSellAug 17, 2026$0.71
Ali FarazSellAug 17, 2026$0.71

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Operating Income-$131.2M-$115.9M-$93.3M
Net Income-$124.1M-$111.1M-$90.6M
Balance Sheet
Total Assets$170.5M$119.9M$146.9M
Equity-$92.9M$123.3M
ROE--119.7%-73.5%
Per Share
EPS$-1.68$-1.31$-0.59
Cash Flow
Operating CF-$102.1M-$90.5M-$68.3M
CapEx$1.2M$1.0M$618K

Source: XBRL data in Tenaya Therapeutics Inc (TNYA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate TNYA share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
TNYA shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202618$20.1M
Q2 202621$21.6M
Q1 202622$20.6M
Q4 202522$19.1M
Q3 202520$27.9M
Q2 202519$9.0M
Q1 202521$7.5M
Q4 202415$10.3M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 158 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

TNYA filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 18, 2026--
4Nov 18, 2026--
10-QNov 4, 2026Analysis
8-KNov 4, 2026Analysis-
4Sep 11, 2026--
4Sep 11, 2026--
4Aug 17, 2026--
4Aug 17, 2026--
8-KAug 5, 2026Analysis-
10-QAug 5, 2026-
4Jul 14, 2026--
8-KJul 2, 2026Analysis-
8-KJun 29, 2026Analysis-
4May 29, 2026-
4May 29, 2026-
4May 29, 2026-
4May 29, 2026-
4May 29, 2026-
4May 29, 2026-
8-KMay 29, 2026-
4May 29, 2026-
4May 19, 2026-
4May 19, 2026-
4May 19, 2026-
8-KMay 6, 2026-

Related Health Care companies

All Health Care →

TNYA SEC filings: frequently asked questions

Are TNYA insiders buying or selling?

In the last 90 days, Tenaya Therapeutics Inc (TNYA) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $2,156 by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold TNYA stock?

As of September 30, 2026, the largest Tenaya Therapeutics Inc (TNYA) holders among the 13F filers tracked by SignalX were Millennium Management ($6.2 million), Vanguard Capital Management LLC ($4.8 million), Citadel Advisors LLC ($2.7 million), BlackRock ($2.5 million), Renaissance Technologies LLC ($1.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What did TNYA report in its latest 8-K?

Tenaya Therapeutics Inc (TNYA) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Tenaya’s earnings release covers the quarter ended September 30, 2026.

What are the latest TNYA SEC filings?

Tenaya Therapeutics Inc (TNYA) filed its latest 10-K annual report on March 11, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 18, 2026.

What is TNYA's SEC CIK number?

Tenaya Therapeutics Inc (TNYA)'s SEC Central Index Key (CIK) is 1858848. EDGAR lists every TNYA filing under that number.

Ask anything about TNYA

The research agent reads TNYA's filings, financials, insider trades and 13F holders, then answers with sources.